ARS Pharmaceuticals (SPRY) Goodwill & Intangibles (2023 - 2026)

ARS Pharmaceuticals has reported Goodwill & Intangibles for 3 years, with the latest figure at $14.2 million in Q1 2026.

• Quarterly Goodwill & Intangibles rose 5547.81% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (up 5547.81% YoY) and the FY2025 annual result came in at $14.5 million, up 96.07% from the prior year.
• Goodwill & Intangibles slipped to $14.2 million in Q1 2026 per SPRY's latest filing, from $14.5 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $14.5 million in Q4 2025 and troughed at $125000.0 in Q3 2025.
• A 3-year average of $8.2 million and a median of $10.2 million in 2024 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2025 and 2026: Goodwill & Intangibles jumped 96.07% in 2025, then jumped 5547.81% in 2026.
• Over 3 years, Goodwill & Intangibles stood at $7.4 million in 2024, then surged by 96.07% to $14.5 million in 2025, then declined by 1.91% to $14.2 million in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $14.2 million, $14.5 million, and $125000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.